

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mega Genomics Limited
美因基因有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6667)

**CONTINUING CONNECTED TRANSACTION
SUPPLEMENTAL ANNOUNCEMENT**

Reference is made to the announcement (the “**Announcement**”) of Mega Genomics Limited (the “**Company**”) dated 5 January 2024 in relation to, among other things, the 2024 Meinian OneHealth Genetic Testing Service Framework Agreement and the 2024 Dr. Yu Genetic Testing Service Framework Agreement. Unless the context otherwise requires, capitalised terms used herein have the same meanings as defined in the Announcement.

In order to comply with Rule 14A.35 of the Listing Rules and to maintain the normal business operation of the Company and to increase the revenue generated from the principal business of the Company, if the annual caps (the “**Meinian OneHealth’s Original Annual Caps**”) in the paragraph “I. PRINCIPAL TERMS OF THE 2024 MEINIAN ONEHEALTH GENETIC TESTING SERVICE FRAMEWORK AGREEMENT – ANNUAL CAPS AND BASIS FOR DETERMINING THE ANNUAL CAPS” and the annual caps (the “**Dr. Yu’s Original Annual Caps**”) in the paragraph “II. PRINCIPAL TERMS OF THE 2024 DR. YU GENETIC TESTING SERVICE FRAMEWORK AGREEMENT – ANNUAL CAPS AND BASIS FOR DETERMINING THE ANNUAL CAPS” in the Announcement are not approved by the Independent Shareholders, the Company will conduct the transactions in accordance with the annual caps as set out below (the “**Replacement Caps**”) to ensure that the transaction amounts will remain below the relevant ratios requiring Independent Shareholders’ approval under the Listing Rules:

THE 2024 MEINIAN ONEHEALTH GENETIC TESTING SERVICE FRAMEWORK AGREEMENT REPLACEMENT CAPS AND BASIS FOR DETERMINING THE ANNUAL CAPS

The Replacement Caps for the transactions under the 2024 Meinian OneHealth Genetic Testing Service Framework Agreement for the three financial years ending 31 December 2024, 2025 and 2026 are set out as follows:

	For the year ended 31 December		
	2024	2025	2026
	<i>RMB million</i>	<i>RMB million</i>	<i>RMB million</i>
Annual cap	8.8	8.8	8.8

The above Replacement Caps are set to ensure compliance with the announcement requirement of the Listing Rules.

THE 2024 DR. YU GENETIC TESTING SERVICE FRAMEWORK AGREEMENT REPLACEMENT CAPS AND BASIS FOR DETERMINING THE ANNUAL CAPS

The Replacement Caps for the transactions under the 2024 Dr. Yu Genetic Testing Service Framework Agreement for the three financial years ending 31 December 2024, 2025 and 2026 are set out as follows:

	For the year ended 31 December		
	2024	2025	2026
	<i>RMB million</i>	<i>RMB million</i>	<i>RMB million</i>
Annual cap	8.8	8.8	8.8

The above Replacement Caps are set to ensure compliance with the announcement requirement of the Listing Rules.

LISTING RULES IMPLICATIONS

As all the applicable percentage ratios (other than the profit ratio) for the 2024 Meinian OneHealth Genetic Testing Service Framework Agreement Replacement Caps and the 2024 Dr. Yu Genetic Testing Service Framework Agreement Replacement Caps are less than 25% and the maximum annual cap is less than HK\$10,000,000, the Replacement Caps are subject to the reporting and announcement requirements under Chapter 14A of the Listing Rules but are exempted from the circular and Independent Shareholders' approval requirements.

The Company will endeavor to obtain the Independent Shareholders' approval for the Meinian OneHealth's Original Annual Caps and the Dr. Yu's Original Annual Caps as soon as possible as disclosed in the Announcement. In the event that the aforesaid approvals are not obtained, the Company will proceed with the transactions under the 2024 Meinian OneHealth Genetic Testing Service Framework Agreement and the 2024 Dr. Yu Genetic Testing Service Framework Agreement in accordance with the Replacement Caps. In the event that the Company obtains the aforesaid approvals, the Company will proceed with the transactions under the 2024 Meinian OneHealth Genetic Testing Service Framework Agreement and the 2024 Dr. Yu Genetic Testing Service Framework Agreement in accordance with the Meinian OneHealth's Original Annual Caps and the Dr. Yu's Original Annual Caps. Prior to the convening of the EGM, the Company will ensure that the transaction amount will not exceed the Replacement Caps as disclosed in this announcement.

Save as disclosed above, the contents of the Announcement remain unchanged and are incorporated by reference into this announcement.

By order of the Board
Mega Genomics Limited
LIN Lin
Executive Director and Chairperson

Hong Kong, 11 January 2024

As at the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin, Mr. Huang Yufeng and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.

* *For identification purpose only*